Compare Mesoblast Limited (MESO) vs Marsh & McLennan Companies, Inc. (MRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Marsh & McLennan Companies, Inc. — how do they compare? Mesoblast Limited trades at $14.29 (market cap $1.75B), while Marsh & McLennan Companies, Inc. trades at $175.76 (market cap $84.31B). The key difference: Marsh & McLennan Companies, Inc. is far larger — about 48.2× Mesoblast Limited's market cap, and Marsh & McLennan Companies, Inc. pays a 2.24% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 15 Days and Marsh & McLennan Companies, Inc. for 109 Days on average.
| MESO | MRSH | |
|---|---|---|
Market Cap | $1.75B | $84.31B |
Volume | 239,027 | 3,948,947 |
Sector | Health | Financials |
52-Week High | $20.96 | $207.02 |
52-Week Low | $13.19 | $157.32 |
Typical Hold Time | 15 Days | 109 Days |
Enterprise Value | $1.83B | $104.99B |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $14.29, up 2.51% today, amid bearish technical signals but positive fundamental developments. The stock shows strong revenue growth with FY2026 reaching $120 million, though profitability remains negative. Recent FDA approval for Ryoncil's potency assay and completion of Phase 3 back pain trials provide catalysts. Technical indicators show oversold conditions with RSI at 22.4, while moving averages signal bearish momentum.
Investment outlook balances high growth potential against persistent losses. The expanding Ryoncil market share and pipeline progress offer upside, but negative margins and cash burn pose risks. Analyst consensus leans bullish with 45% buy ratings, yet the stock faces execution challenges in achieving profitability amid competitive pressures.
Marsh (MRSH) trades at $175.76, up 1.21% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust fundamentals, including a 25.72% ROE and 14.24% net income margin, alongside the recent acquisition of Accel Holdings announced on October 2, 2026. Revenue has grown steadily, reaching $27.0B in 2025, though profit margins have slightly softened.
The outlook remains positive with a consensus price target of $202.71, implying 15% upside, but risks include high valuation multiples and competitive pressures. Analysts are predominantly neutral, with 65% hold ratings, suggesting cautious optimism amid solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Marsh & McLennan Companies, Inc.
Marsh & McLennan Companies Inc is a professional services firm that provides advice and solutions in the areas of risk, strategy, and human capital. The company operates through two main segments: risk and insurance services and consulting. In risk and insurance services, the firm offers services via Marsh (an insurance broker) and Guy Carpenter (a risk and reinsurance specialist). The consulting division comprises Mercer (a provider of human resource services) and Oliver Wyman (management and economic consultancy).
Read more on MRSH →
